share_log

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2

HC Wainwright & Co.对协同诊断保持中立,将目标股价下调至2美元
Benzinga ·  2023/08/14 06:46

HC Wainwright & Co. analyst Yi Chen maintains Co-Diagnostics (NASDAQ:CODX) with a Neutral and lowers the price target from $3 to $2.

HC Wainwright&Co.分析师陈毅维持共同诊断公司(纳斯达克代码:CODX)的中性,并将目标价从3美元下调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发